Patrick Heron

Board Member

Patrick Heron, a co-founder of Arcutis, has served on Arcutis board since 2016, and was the chair from December 2019 to November 2024. Mr Heron is a managing general partner of Frazier’s Life Sciences team. He joined the firm in 1999 and opened Frazier’s Menlo Park office in 2003. Throughout his tenure as a general partner, Mr Heron has led or co-led investments across over 30 companies. Mr Heron has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage anti-infectives companies to >$100 million commercial-stage dermatology companies. Patrick has also been active in company formation around both early- and later-stage assets. He has led and served as director for many successful Frazier Life Sciences investments, including ARMO (acquired by Eli Lilly), Ignyta (acquired by Roche), Silvergate Pharmaceuticals (acquired by CutisPharma), Tobira Therapeutics (acquired by Allergan), Marcadia (acquired by Roche), Calixa (acquired by Cubist), Cerexa (acquired by Forest), PreCision Dermatology (acquired by Valeant), MedPointe (acquired by Meda), and Collegium (NASDAQ: COLL). He currently serves on the boards of HilleVas, MBX Biosciences, Mirum Pharmaceuticals, and Scout Bio. He is also a board observer for Aspen Neuroscience. Prior to joining Frazier, Mr Heron helped develop McKinsey & Company’s West Coast biotechnology consulting practice, where he led projects involving mergers and acquisitions, product launches, sales force optimization, corporate partnering, and research prioritization.

Mr Heron received his MBA from Harvard Business School. He also holds a BA from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar.